1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
3
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yamamoto H, Yatabe Y and Toyooka S:
Inherited lung cancer syndromes targeting never smokers. Transl
Lung Cancer Res. 7:498–504. 2018. View Article : Google Scholar : PubMed/NCBI
|
6
|
Subramanian J and Govindan R: Molecular
genetics of lung cancer in people who have never smoked. Lancet
Oncol. 9:676–682. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Brennan P, Hainaut P and Boffetta P:
Genetics of lung-cancer susceptibility. Lancet Oncol. 12:399–408.
2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Sun H, Lesche R, Li DM, Liliental J, Zhang
H, Gao J, Gavrilova N, Mueller B, Liu X and Wu H: PTEN modulates
cell cycle progression and cell survival by regulating
phosphatidylinositol 3, 4, 5,-trisphosphate and Akt/protein kinase
B signaling pathway. Proc Natl Acad Sci USA. 96:6199–6204. 1999.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F,
Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z and Chun-Sheng
K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell
proliferation and radioresistance by targeting PTEN. BMC Cancer.
10:3672010. View Article : Google Scholar : PubMed/NCBI
|
11
|
Li XT, Li JC, Feng M, Zhou YX and Du ZW:
Novel lncRNA-ZNF281 regulates cell growth, stemness and invasion of
glioma stem-like U251s cells. Neoplasma. 66:118–127. 2019.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhao D, Zhuang N, Ding Y, Kang Y and Shi
L: miR-221 activates the NF-κB pathway by targeting A20. Biochem
Biophys Res Commun. 472:11–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
13
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Sun Z, Aubry MC, Deschamps C, Marks RS,
Okuno SH, Williams BA, Sugimura H, Pankratz VS and Yang P:
Histologic grade is an independent prognostic factor for survival
in non-small cell lung cancer: An analysis of 5018 hospital-and 712
population-based cases. J Thorac Cardiovasc Surg. 131:1014–1020.
2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Rinkenbaugh AL and Baldwin AS: The NF-κB
pathway and cancer stem cells. Cells. 5:162016. View Article : Google Scholar
|
17
|
Li F, Zhang J, Arfuso F, Chinnathambi A,
Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: NF-κB in cancer
therapy. Arch Toxicol. 89:711–731. 2015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Pineau P, Volinia S, McJunkin K, Marchio
A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and
Dejean A: miR-221 overexpression contributes to liver
tumorigenesis. Proc Natl Acad Sci USA. 107:264–269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Yamashita R, Sato M, Kakumu T, Hase T,
Yogo N, Maruyama E, Sekido Y, Kondo M and Hasegawa Y: Growth
inhibitory effects of miR-221 and miR-222 in non-small cell lung
cancer cells. Cancer Med. 4:551–564. 2015. View Article : Google Scholar : PubMed/NCBI
|